MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will present at the 20th Annual BIO CEO & Investor Conference in New York, NY on Monday, Feb. 12, 2018 at 10:15 a.m. ET in the Wilder Room at the New York Marriott Marquis.
BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Sponsored by the Biotechnology Innovation Organization, the world's largest biotech trade association, BIO CEO provides a neutral forum where institutional investors, industry analysts and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a
biopharmaceutical company focused on the development of novel therapies
for patients with diseases of the central and peripheral nervous system.
The Company is headquartered in Bresso near Milan, Italy. Xadago®
(safinamide) has received marketing authorization for the treatment of
Parkinson’s disease in the European Union, Switzerland and the USA, and
is commercialized by Newron’s Partner Zambon. US WorldMeds holds the
commercialization rights in the USA. Meiji Seika has the rights to
develop and commercialize the compound in Japan and other key Asian
territories. In addition to Xadago® for Parkinson’s disease, Newron has
a strong pipeline of promising treatments for rare disease patients at
various stages of clinical development, including sarizotan for patients
with Rett syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing Evenamide as the potential first
add-on therapy for the treatment of patients with positive symptoms of
schizophrenia. For more information, please visit: http://www.newron.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180206005061/en/
